TMCnet News

Sign Up For Our Free Newsletter and Make Money!! SKGO,PBME,TSHO,OPSY,GOVX,ZYXI
[November 19, 2009]

Sign Up For Our Free Newsletter and Make Money!! SKGO,PBME,TSHO,OPSY,GOVX,ZYXI

(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (PINKSHEETS: SKGO) Skybridge Technology Group, Inc., (OTCBB: PBME) Pacific Biometrics, Inc., (OTCBB: TSHO) Tradeshow Marketing Company, Ltd., (PINKSHEETS: OPSY) Optical Systems, Inc., (OTCBB: GOVX) GeoVax Labs, Inc., (OTCBB: ZYXI) Zynex, Inc. To sign up for our free Profiles & Alerts :: visit email us!! or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: SKGO - Skybridge Technology Group, Inc.) LATEST NEWS!! SkyBridge Technology Group Inc. (SKGO) General Update TORONTO, Nov 18, 2009 -- SkyBridge Technology Group Inc. (SKGO) is providing its followers and shareholders with a brief update vis a vis general business matters.

The company is introducing its new corporate domain name WWW.SKYBRIDGETECHGROUP.COM together with a small interim corporate web site. A full, elaborate, professionally built web site will be launched in concert with the upcoming targeted merger.

The interim CEO Marc Pintar said "SKGO lead merger advisor Mina Mar Group ( has presented to the newly elected board of SKGO several merger candidates, including a USA based automotive industry candidate, and a China based manufacturing company. Both targeted companies have significant assets and revenues. SKGO representatives will be in China from Nov 24 to Nov 28 for the purpose of conducting due diligence of the China targeted company. Notwithstanding, discussions are continuing with both targeted merger candidate companies. The SKGO board is aiming to have all the mergers and corporate organization complete by the end of the year, which will allow SKGO' to have a running start in 2010." In other company news, the company continues with its aspirations for the end of November to complete its financial filings with Pink Sheets including its Q3 report which should earn the company a "Yield" or the top 2 tier ranking with Pink Sheets.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today at Safe Harbor Statement ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: PBME - Pacific Biometrics, Inc.) LATEST NEWS!! Pacific Biometrics Inc. Reports First Quarter Operating Results --Revenue Increased 27% From Prior-Year Period SEATTLE, Nov 16, 2009 -- Pacific Biometrics, Inc. (OTC Bulletin Board: PBME) ("PBI" or "the Company"), a leading provider of specialty central laboratory and clinical biomarker services, today announced its operating results for the first quarter of FY2010. The Company will host an investor conference call to discuss its FY2010 first quarter operating results at 4:15 p.m. EST today (see details below).

For the three months ended September 30, 2009, revenues increased 27% to $2,301,375, compared with $1,805,042 in the first quarter of the previous fiscal year. The Company posted an operating loss of $213,708 in the most recent quarter, versus an operating loss of $213,372 in the prior-year period. The Company reported a net loss of $273,150, or $0.01 per share, in the most recent quarter, versus a net loss of $5,737, or $0.00 per share, in the corresponding period of the previous fiscal year. The increase in net loss was primarily due to the fact that in the first quarter of FY2009 the Company recorded a significant non-cash gain related to convertible debt that was then outstanding.

"We are pleased that our first quarter revenues were 27% above last year's levels," commented Ron Helm, Chairman and Chief Executive Officer of Pacific Biometrics, Inc. "Having said that, we did not reach our internal revenue goal, in part because of the early termination of several clinical studies for reasons unrelated to our performance. Unfortunately, studies are sometimes terminated unexpectedly by clinical trial sponsors, for a variety of reasons, prior to the completion of our work under the terms of the original contracts. This is simply a feature of our business. We also cannot ignore the ongoing economic difficulties that continue to impact the clinical trials industry, combined with the impact of tight credit markets on spending and investment in all sectors of our markets." "Although our gross profit margins improved and our SG&A expense ratio declined relative to the prior-year period, we still recorded an operating loss in this year's first quarter. This reflects, in large part, the significant and ongoing investments we are making in our clinical biomarker services business, which we continue to see as a major growth opportunity going forward. Despite the decline in first quarter net income, I am pleased to report that PBI continued to generate positive cash flow from operating activities during the three months ended September 30, 2009." "Based on our internal financial metrics, we are optimistic that our revenues for fiscal 2010 will exceed the record revenues achieved in fiscal 2009," Mr. Helm continued. "We are encouraged by the substantial requests for proposals received from new and existing customers in recent months, and I am confident that PBI's scientific, technical and operational capabilities, combined with a more aggressive business development strategy, will allow us to capture our fair share of these new contract opportunities. Also, our continued focus on biomarkers is gaining traction in a market that is experiencing significant growth in outsourced lab services and in which there are as yet no dominant industry leaders. To further capitalize on these trends, we are investing in new instrument platforms that will allow us to broaden our therapeutic areas of expertise and open up additional growth opportunities." For additional information, see Pacific Biometrics' Annual Report on Form 10K for the fiscal year ended June 30, 2009 and the Quarterly Report on Form 10-Q for the three months ended September 30, 2009, available on the SEC's website at

Investor Conference Call Pacific Biometrics, Inc. will host an investor conference call to discuss its first quarter FY2010 operating results, along with other relevant subjects at 4:15 p.m. EST (1:15 p.m. PST) today -- Monday, November 16, 2009.

Stockholders and other interested parties may listen to the conference call by dialing 800-860-2442 (international/local participants dial 412-858-4600) and requesting the "Pacific Biometrics, Inc. Conference Call" a few minutes before 4:15 p.m. EST on November 16, 2009. A replay of the conference call will be available one hour after the call through Monday, November 23, 2009 at 5:00 p.m. EDT by dialing 877-344-7529 (international/local participants dial 412-317-0088) and entering the Conference ID 435436.

About Pacific Biometrics, Inc. (PBI) Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBME". For more information about PBI, visit the company's web site at

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: TSHO - Tradeshow Marketing Company, Ltd.) LATEST NEWS!! Tradeshow Marketing Company Provides Update on Infomercial Production SAMMAMISH, WA, Nov 17, 2009 -- Tradeshow Marketing Company, Ltd. (OTC: TSHO) provided a progress report today on the production of its DRTV infomercial.

Cesari Direct has finished the principal production of the short form television commercial. The post-production process has begun, which includes editing footage, graphics, voiceover, animation, and music. There is the potential for an additional pick-up shoot day to obtain footage to complement the original shooting. The collaborative process usually takes two to three weeks.

"I am pleased with the progression of the commercials for Tradeshow Marketing. Each round of review with our client makes the commercials more compelling. We're excited to launch this campaign," said Rick Cesari, CEO and Founder of Cesari Direct.

Additionally, Cesari Direct is currently leading the strategic selection of the DRTV campaign partners. Tradeshow Marketing will be engaging an inbound telesales call center, a fulfillment and distribution center, a specialized website development and ecommerce firm, an online marketing firm, and a merchant processing firm. Proposals from the potential partners were received through an RFP process and are currently under review. The engagements with the selected partners should be completed within the next two weeks.

"Cesari Direct has deep relationships with a wide variety of DRTV component partner firms. Our collective expertise will allow Tradeshow Marketing to select the firm in each component area that best matches its requirements," commented Tim O'Brien, VP of Business Development and Campaign Management, Cesari Direct. He continued that, "Cesari Direct looks forward to integrating with each partner to build out this direct to consumer marketing platform for the Tradeshow Marketing Company" Luniel de Beer, CEO of Tradeshow Marketing, commented that, "We are excited that the campaign preparation process is almost complete. I am very pleased with Cesari Direct's attention to detail on all the logistical and operational aspects of the campaign, and I'm anticipating a successful launch in the coming weeks." The company also indicated that they are working on a full product announcement to be provided once the infomercial and product website production has been completed, which will mark the official launch of the television campaign.

About Cesari Direct Founded in 1993, Cesari Direct ( produces both long and short form direct response television campaigns, and provides media buying, online marketing, and campaign management services. Rick Cesari, Founder and CEO, has long been considered a pioneer in the DRTV industry, having created and produced more than 75 successful infomercial campaigns including the Juiceman Juicer, the George Foreman Grill, the Sonicare toothbrush, and OxiClean.

About The Tradeshow Marketing Company The Tradeshow Marketing Company, Ltd. is a publicly-traded consumer products company focused on the development and distribution of unique products that have broad appeal and improve the lives of consumers. The company operates a direct demonstration business via trade shows and exhibitions throughout North America, and various product-specific e-commerce web sites. The company was established in 2003, and is headquartered in Sammamish, Washington.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: OPSY - Optical Systems, Inc.) LATEST NEWS!! Optical Systems, Inc. Launches New Version of Its Flagship CRM Product, Save-a-Deal --Save-a-Deal 2010 software product is designed to help dealerships retain customers and reduce sales costs HOUSTON, Nov 16, 2009 -- Automotive Software Designers, Inc., a leading provider of software and services for the automotive retail industry and a wholly owned subsidiary of Optical Systems, Inc. (Pink Sheets: OPSY), today announced the launch of Save-a-Deal 2010, the latest version of its flagship, customer relationship management (CRM) software for automotive dealerships across the United States.

"The sooner-than-expected launch of Save-a-Deal 2010 is a huge milestone for the company," said B.J. Grisaffi, Chairman and Chief Executive Officer of Optical Systems, Inc. "We believe Save-a-Deal 2010 is the most robust CRM software solution for auto dealerships on the market today. We have already received inquiries from several, large automotive groups and expect to have a marketing agreement signed in the next few weeks to rapidly expand our presence into key markets within the U.S." Save-a-Deal is a comprehensive, fully-integrated front office software solution specifically designed to increase auto dealerships' profitability. When properly used, this scalable CRM system is guaranteed to increase unit sales and profit-per-vehicle, while lowering costs through enhanced efficiency.

Save-a-Deal 2010 is a more streamlined, cost-effective CRM solution than its predecessor with added capabilities in remote personnel management, customer service, training, and security.

New features of Save-a-Deal 2010 include: -- Real-time access speeds with normal content loads of more than 200,000 database records from three different states with multiple, concurrent users -- Added scalability from modular software architecture -- Significant savings on installation and maintenance costs -- Three levels of security to ensure protection of dealerships' sensitive data and information -- More customization for electronic records management "Save-a-Deal 2010 enables auto dealerships to more effectively manage people and processes to achieve operational excellence," said Grisaffi.

About Optical Systems, Inc.

Optical Systems, Inc., through its operating subsidiary, Automotive Software Designers, Inc., develops technology and services for the automotive retail industry designed to maximize productivity and increase profits at auto dealerships. ASDI's flagship technology solution, Save-a-Deal, is a turnkey customer relationship management (CRM) tool for auto dealerships. Our business development center (BDC) provides a variety of services designed to help auto dealerships drive traffic to their showroom or Web site, retain customers and generate new streams of revenue. For more information, visit ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: GOVX - GeoVax Labs, Inc.) LATEST NEWS!! FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting ATLANTA, Nov 17, 2009 -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV. The meeting will only take place if the Company is not satisfied or requires some clarification to the FDA's answers to the questions submitted in the pre-IND package. Following the FDA response to the Pre-IND meeting questions, GeoVax will prepare and submit to the FDA an IND application for the therapeutic trial.

Robert McNally, Ph.D., president and chief executive officer, stated, "In anticipation of a pre-IND meeting in mid December, we have submitted a pre-IND information packet to the FDA. This packet includes rationale and supporting data for each question in the pre-IND package to allow a response from the FDA. The main purpose of the Pre-IND meeting is to ensure the FDA understands the purpose, approach and endpoints for the anticipated Phase 1 therapeutic trial and that we have answers to all of our questions to the FDA prior to filing the actual IND.

"While there are no guarantees of success for our therapeutic IND package, the pre-IND process helps ensure that our IND will adequately address any concerns the FDA may have about the proposed therapeutic trial," Dr. McNally added. "We understand the extreme need for this vaccine and we understand the process necessary to navigate forward." A new IND with the FDA is required since this will be the first time the GeoVax vaccine will be used for a therapeutic application. The Phase 1 therapeutic protocol stresses safety parameters to minimize any risk to the volunteers. The protocol, conceived with collaboration from ARCA (AIDS Research Consortium of Atlanta), has specific objectives to optimize safety while evaluating the ability for the vaccine to elicit protective immune responses in vaccinated participants. The proposed trial is based on the achievement of excellent post-vaccine viral control in animal trials conducted in recently infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University. The proposed human trial follows the precedents set in the preclinical animal trials and is a critical step towards developing a therapeutic vaccine for HIV-1 infected humans.

The IND process is expected to take a number of months to complete. Based on the Company's current progress, commencement of the trial is targeted for early 2010.

HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America, where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: ZYXI - Zynex, Inc.) LATEST NEWS!! Zynex Reports Revenue and Profit in Third Quarter, 2009 LITTLETON, Colo., Nov 17, 2009 -- Zynex, Inc. (OTCBB:ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, reports its financial results for the third quarter of 2009. Revenue increased 113% to $4,690,715 and net income increased to $458,640 for the quarter.

Net rental and sales income for the quarter ended September 30, 2009 increased 113% to $4,690,715 compared with $2,198,738 for the same quarter of 2008. Gross profit for the three months ended September 30, 2009 was $3,793,487 or 80.9% of net revenue compared to 79.4% for the 2008 third quarter. Net income for the third quarter of 2009 increased to $458,640 compared to a net loss of $366,419 for the same period one year ago. Net cash provided by operating activities was $1,761,624 for the nine months ended September 30, 2009.

Thomas Sandgaard, President and CEO of Zynex, said: "We are excited to see our net revenue, net income and positive cash flow from operations continue to grow in 2009 compared to the same period in 2008. Our earnings per share (EPS trailing twelve months as of September 30, 2009) is now 7 cents per share which we consider a very positive development." Third Quarter Ended September 30 3 Months 9 Months 2009 2008 2009 2008 Net Sales and Rental Income $4,690,715 $2,198,738 $13,269,637 $7,827,919Net Income (Loss)                $458,640       $(366,419)       $2,118,054      $152,301 Net Income per share - Basic     $0.02          $(0.01)          $0.07           $0.01 Common Shares Used in Computing per Share Amount - Basic         30,086,784     29,311,220       29,997,276       28,722,456 Net Income (Loss) per share - Diluted                        $0.02          $(0.01)          $0.07            $0.00 Common Shares Used in Computing per Share Amount - Diluted       30,282,030     29,311,220       30,223,547       30,576,626 About Zynex Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.

------------------------------------------------------------------------------------------------------------------------------------------------------------ About is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to (c) 2009 M2 COMMUNICATIONS

[ Back To's Homepage ]